Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel (Testosterone 50–100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up.
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2014
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Bayer
- 07 Jul 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
- 07 Oct 2008 Actual number of patients (363) and trial identifier (91297) added as reported by CT.gov
- 07 Oct 2008 Actual end date (Oct 2007) added as reported by CT.gov